Pepgen Inc. (PEPG)

$10.535

-1.31

(-11.06%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Pepgen Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 64.5%

Performance

  • $10.40
    $12.25
    $10.54
    downward going graph

    1.38%

    Downside

    Day's Volatility :15.14%

    Upside

    13.96%

    downward going graph
  • $3.72
    $17.51
    $10.54
    downward going graph

    64.71%

    Downside

    52 Weeks Volatility :78.75%

    Upside

    39.81%

    downward going graph

Returns

PeriodPepgen Inc.Sector (Health Care)Index (Russel 2000)
3 Months
53.35%
-0.4%
0.0%
6 Months
90.51%
8.5%
0.0%
1 Year
-16.12%
4.2%
-1.2%
3 Years
-11.47%
13.9%
-19.2%

Highlights

Market Capitalization
383.2M
Book Value
$4.55
Earnings Per Share (EPS)
-3.3
Wall Street Target Price
21.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-29.39%
Return On Equity TTM
-54.59%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-83.6M
Diluted Eps TTM
-3.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.89
EPS Estimate Next Year
-2.68
EPS Estimate Current Quarter
-1.01
EPS Estimate Next Quarter
-1.03

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Pepgen Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 105.03%

Current $10.54
Target $21.60

Technicals Summary

Sell

Neutral

Buy

Pepgen Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pepgen Inc.
Pepgen Inc.
-29.15%
90.51%
-16.12%
-11.47%
-11.47%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pepgen Inc.
Pepgen Inc.
NA
NA
NA
-2.89
-0.55
-0.29
NA
4.55
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pepgen Inc.
Pepgen Inc.
Buy
$383.2M
-11.47%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • RA Capital Management, LLC

    25.13%
  • Viking Global Investors LP

    4.58%
  • Adage Capital Partners Gp LLC

    3.40%
  • HHG PLC

    3.05%
  • FMR Inc

    2.28%
  • BlackRock Inc

    2.24%

Company Information

Organization
Pepgen Inc.
Employees
64
CEO
Dr. James G. McArthur Ph.D.
Industry
Services

FAQs